scholarly journals Evaluation of Long-term Oncological Outcomes of Inter-Sphincter Resection Compared with Traditional Abdominoperineal Resection in Treatment of Low Rectal Cancers: A Cross Sectional Study

Author(s):  
FakhroSadat Anaraki ◽  
Mahdi Alemrajabi ◽  
Ramin Shekouhi ◽  
Maryam Sohooli ◽  
Seyed-Ali Sabz

Abstract Objectives abdominoperineal resection (APR), is considered the gold standard surgical treatment for low rectal cancer. Patients with low rectal tumors, tumor’s distance less than 5 cm from the anal verge, are likely to require permanent colostomy after APR. Thus, anus-preserving alternative procedures have been tested to avoid the need for permanent colostomy. the aim of the present study is to compare the functional results, and oncological outcome of traditional APR method. Methods Patients' demographic information as well as tumor characteristics were evaluated through a patient's information form. All patients were followed after the operation every three months for two years, and then every six months for at least three years. Results The study was performed on 60 patients with rectal cancer. In the group that performed APR, 9 (30%) patients developed with disease recurrence. In the ISR group, 10 (33.3%) had relapses. Based on this result, the two groups were nearly similar in the recurrence rate of disease and the difference between these two groups was not statistically significant (P value = 0.8). Conclusion In summary, the results of the present study concluded that there is no significant difference in efficacy of ISR method compared with the conventional APR in treatment of ultra-low rectal cancer. We surveyed that the ISR method is associated with beneficial long-term survival. Considering the post-operation complication associated with APR surgery including permanent colostomy, and disappointing functional outcomes, we encourage physicians to expand the use of anus-preserving procedures in treatment of low-grade distal rectal cancer.

2021 ◽  
Author(s):  
Xinlong Li ◽  
Xiangyuan Li ◽  
Rongrong Fu ◽  
Derry Minyao Ng ◽  
Tong Yang ◽  
...  

Abstract Background: The impact of neoadjuvant therapy on the long-term prognosis of patients with resectable rectal cancer is controversial. This study aimed to explore the effect of neoadjuvant therapy on the long-term prognosis of patients with resectable rectal cancer. Methods: Four major databases (PubMed, Web of Science, Embase, Cochrane library) were searched to find relevant articles published between January 2000 and July 2020. The main outcome indicators were the 5-year overall survival (OS) and disease-free survival (DFS). Results: Compared with upfront surgery, our meta-analysis showed that 5-year OS (HR: 0.84, 95% Cl: 0.78-0.91) and DFS (HR: 0.91, 95% Cl: 0.87-0.95) were prolonged for patients with resectable rectal cancer after receiving neoadjuvant therapy. The results of subgroup analysis suggested that both neoadjuvant short-course radiotherapy (SCRT) and neoadjuvant chemo-radiotherapy (CRT) could improve the 5-year OS and DFS. The 5-year OS and DFS of patients with stage Ⅱ-Ⅲ rectal cancer increased significantly and the improvement of 5-year OS and DFS could also be observed in mid/low rectal cancer.Conclusion: Neoadjuvant therapy could improve the long-term survival of patients with mid/low rectal cancer in stage Ⅱ-Ⅲ. For the treatment, neoadjuvant SCRT and neoadjuvant CRT were recommended.


Author(s):  
Xinlong Li ◽  
Xiangyuan Li ◽  
Rongrong Fu ◽  
Derry Ng ◽  
Tong Yang ◽  
...  

Background: The impact of neoadjuvant therapy on long-term prognosis of patients with resectable rectal cancer is currently unknown. Objective: This study aimed to explore the long-term prognosis of patients with resectable rectal cancer following treatment with neoadjuvant therapy. Methods: Four major databases (PubMed, Web of Science, Embase, Cochrane library) were searched to identify relevant articles published between January 2000 and July 2020. The main outcome indicators were the 5-year overall survival (OS) and disease-free survival (DFS). Results: The meta-analysis revealed that 5-year OS (HR: 0.88, 95% Cl: 0.83-0.93) and DFS (HR: 0.95, 95% Cl: 0.91-0.98) were higher in patients with resectable rectal cancer after receiving neoadjuvant therapy than those treated with upfront surgery. Subgroup analysis demonstrated that the long-term survival of patients in Asia and Europe could benefit from neoadjuvant therapy. The neoadjuvant short-course radiotherapy (SCRT) and neoadjuvant chemo-radiotherapy (CRT) improved the 5-year OS and DFS of patients with stage Ⅱ-Ⅲ rectal cancer and mid/low rectal cancer. Further research found that patients with stage Ⅱ only had an increase in OS, while patients with stage Ⅲ have improved 5-year OS and DFS. Conclusion: Neoadjuvant therapy improved the long-term survival of patients with mid/low rectal cancer in stage Ⅱ-Ⅲ (especially stage Ⅲ). Additionally, patients in Asia and Europe seemed to be more likely to benefit from neoadjuvant therapy. For the treatment, we recommend neoadjuvant SCRT and neoadjuvant CRT for resectable rectal cancer.


2012 ◽  
Vol 28 (4) ◽  
pp. 503-510 ◽  
Author(s):  
Thilo Welsch ◽  
Vyron Mategakis ◽  
Pietro Contin ◽  
Yakup Kulu ◽  
Markus W. Büchler ◽  
...  

2021 ◽  
Author(s):  
Xinlong Li ◽  
Xiangyuan Li ◽  
Rongrong Fu ◽  
Derry Minyao Ng ◽  
Tong Yang ◽  
...  

Abstract Background: The impact of neoadjuvant therapy on the long-term prognosis of patients with resectable rectal cancer is controversial. This study aimed to explore the effect of neoadjuvant therapy on the long-term prognosis of patients with resectable rectal cancer. Methods: Four major databases (PubMed, Web of Science, Embase, Cochrane library) were searched to find relevant articles published between January 2000 and July 2020. The main outcome indicators were the 5-year overall survival (OS) and disease-free survival (DFS). Results: Compared with upfront surgery, our meta-analysis showed that 5-year OS (HR: 0.84, 95% Cl: 0.78-0.91) and DFS (HR: 0.91, 95% Cl: 0.87-0.95) were prolonged for patients with resectable rectal cancer after receiving neoadjuvant therapy. The results of subgroup analysis suggested that both neoadjuvant short-course radiotherapy (SCRT) and neoadjuvant chemo-radiotherapy (CRT) could improve the 5-year OS and DFS. The 5-year OS and DFS of patients with stage Ⅱ-Ⅲ rectal cancer increased significantly and the improvement of 5-year OS and DFS could also be observed in mid/low rectal cancer.Conclusion: Neoadjuvant therapy could improve the long-term survival of patients with mid/low rectal cancer in stage Ⅱ-Ⅲ. For the treatment, neoadjuvant SCRT and neoadjuvant CRT were recommended.


Sign in / Sign up

Export Citation Format

Share Document